Rheumatoid Arthritis, DMARD-naive and Early Disease Patients

Immunology

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Immunology is a $15.0B market in mature growth, driven by blockbuster JAK inhibitors and biologics across multiple therapeutic domains.

$15.0B marketMature↑ Growing30 products15 companies

Key Trends

JAK inhibitors and corticosteroid combinations dominate spending (39% combined)
Multiple patent cliffs emerging 2026-2028, creating generic competition risk
Robust pipeline with 4,996 trials signals continued innovation and market expansion

Career Verdict

Strong career opportunity for those targeting Medical Affairs, Commercial, or R&D roles, with solid hiring momentum and premium salaries in specialized functions.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#	Product	Company	Revenue	Share	Stage	Trend	LOE
1	MOUNJARO (TIRZEPATIDE)	Eli Lilly and Company	$2.4B	16%	PEAK	Growing	15.7yr
2	SYMBICORT (BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE)	AstraZeneca	$2.0B	13%	LOE_APPROACHING	Stable
3	JAKAFI (RUXOLITINIB)	Incyte	$1.9B	13%	LOE_APPROACHING	Declining	2.6yr
4	RESTASIS (CYCLOSPORINE)	AbbVie	$1.5B	10%	PEAK	Stable	8.0yr
5	RINVOQ (UPADACITINIB)	AbbVie	$976M	7%	PEAK	Growing	11.8yr

#1MOUNJARO

$2.4B

Eli Lilly and Company·PEAK15.7yr

#2SYMBICORT

$2.0B

AstraZeneca·LOE_APPROACHING

#3JAKAFI

$1.9B

Incyte·LOE_APPROACHING2.6yr

#4RESTASIS

$1.5B

AbbVie·PEAK8.0yr

#5RINVOQ

$976M

AbbVie·PEAK11.8yr

Drug Class Breakdown

Janus Kinase Inhibitors

$3.0B(20%)

dominant class with patent cliff risk

Corticosteroid Hormone Receptor Agonists

$2.8B(19%)

established, mature market segment

G-Protein-linked Receptor Interactions

$2.4B(16%)

driven by single blockbuster

Calcineurin Inhibitors

$1.6B(11%)

established immunosuppression class

Tumor Necrosis Factor Receptor Blocking Activity

$1.2B(8%)

legacy biologic class with competition

Career Outlook

Growing

Immunology offers a maturing but actively growing market with strong corporate investment, deep pipelines, and premium compensation across commercial and clinical functions. The therapeutic area is characterized by complex mechanism-of-action portfolios, frequent label expansion opportunities, and multi-indication blockbusters that require sophisticated Medical Affairs and Commercial expertise. Patent cliff risk on JAK inhibitors creates both disruption and opportunity for those skilled in competitive positioning and pipeline strategy.

Breaking In

Enter through Medical Affairs, Clinical Operations, or Commercial Training programs at large companies (J&J, AbbVie, Bristol Myers Squibb); a foundation in immunology mechanisms is valuable but trainable.

For Experienced Professionals

Leverage patent cliff risk to position yourself in competitive differentiation, pipeline strategy, or M&A integration roles, where demand for immunology expertise is highest.

In-Demand Skills

Medical Affairs and MSL expertise in immunosuppression and inflammatory diseasesJAK inhibitor mechanism expertise and competitive positioningClinical trial design and phase transition managementCommercial acumen for premium-priced biologics and small moleculesRegulatory strategy for label expansions and lifecycle management

Best For

Medical Science LiaisonBrand ManagerSenior Medical Affairs ManagerClinical Development ManagerCommercial Strategy Lead

Hiring Landscape

$212K-$387K

Immunology hiring totals 340 open positions with strong demand across Medical Affairs (110 roles, $257K avg), Commercial (83 roles, $270K avg), and R&D (31 roles, $387K avg). Johnson & Johnson, Bristol Myers Squibb, and AbbVie are the top recruiters, reflecting their portfolio depth and market dominance. Compensation is competitive, particularly in R&D and Clinical Operations.

340

Open Roles

Companies Hiring

Departments

Top Hiring Companies

By Department

Medical Affairs(32%)

$257K

Commercial(24%)

$270K

Research & Development(9%)

$387K

Clinical Operations(4%)

$345K

Manufacturing(2%)

$212K

Strong hiring demand with premium compensation in Medical Affairs and Commercial roles; R&D positions command highest salaries but are less abundant.

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Rottapharm BiotechItaly - Monza

1 program

CR6086Phase 21 trial

Active Trials

NCT03163966Completed248Est. Jan 2019

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Rottapharm BiotechCR6086

Clinical Trials (1)

Total enrollment: 248 patients across 1 trials

NCT03163966 Rottapharm BiotechCR6086

A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis

Start: Oct 2017Est. completion: Jan 2019248 patients

Phase 2Completed

Related Jobs in Immunology

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Rheumatoid Arthritis(851)Atopic Dermatitis(457)Psoriasis(421)Ulcerative Colitis(274)Crohn's Disease(264)Systemic Lupus Erythematosus(255)Arthritis, Rheumatoid(209)Plaque Psoriasis(140)Crohn Disease(89)Psoriasis Vulgaris(82)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.